Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IOKOV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-BCMA J6M0-SG3249
|
|||||
| Synonyms |
Anti-BCMA-J6M0 SG3249
Click to Show/Hide
|
|||||
| Organization |
MedImmune LLC
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Multiple myeloma [ICD11:2A83]
Investigative
Plasma cell myeloma [ICD11: 2A83]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.8
|
|||||
| Antibody Name |
Anti-BCMA antibody J6M0
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
SG3199
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
CL2A
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
SG3249
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.82 nM | Moderate BCMA expression (BCMA++) | ||
| Method Description |
The ability of the ADCs to kill multiple myeloma cells in vitro inthe presence of soluble BCMA (sBCMA, 0 ng/ml) as compared to the 09-SG3249 ADC was evaluated in MM.1S cells, except that tested cell lines also were treated with BCMA-containing conditioned media collected from Ad293 cells expressing human BCMA.
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 12.83 nM | Moderate BCMA expression (BCMA++) | ||
| Method Description |
The ability of the ADCs to kill multiple myeloma cells in vitro inthe presence of soluble BCMA (sBCMA, 75 ng/ml) as compared to the 09-SG3249 ADC was evaluated in MM.1S cells, except that tested cell lines also were treated with BCMA-containing conditioned media collected from Ad293 cells expressing human BCMA.
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 32.26 nM | Moderate BCMA expression (BCMA++) | ||
| Method Description |
The ability of the ADCs to kill multiple myeloma cells in vitro inthe presence of soluble BCMA (sBCMA, 270 ng/ml) as compared to the 09-SG3249 ADC was evaluated in MM.1S cells, except that tested cell lines also were treated with BCMA-containing conditioned media collected from Ad293 cells expressing human BCMA.
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 92.92 nM | Moderate BCMA expression (BCMA++) | ||
| Method Description |
The ability of the ADCs to kill multiple myeloma cells in vitro inthe presence of soluble BCMA (sBCMA, 720 ng/ml) as compared to the 09-SG3249 ADC was evaluated in MM.1S cells, except that tested cell lines also were treated with BCMA-containing conditioned media collected from Ad293 cells expressing human BCMA.
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.